Public consultation on HPV vaccines guidance opens
ECDC invites citizens, organisations and public authorities to contribute their views in a public consultation on new guidance for the introduction of human papillomavirus (HPV) vaccines in EU countries. The guidance is the result of a systematic review and grading of the available evidence of the efficacy and effectiveness of the nine-valent HPV vaccine and also looks at the cost-effectiveness of adding boys to the girls-only HPV vaccination strategy.
Stakeholders and interested parties can submit their comments by 29 April 2019. Below you will find the main report, related files and guidelines how to submit the comments.
About the guidance
The last ECDC guidance on the introduction of HPV vaccines in EU countries was issued in 2012. Since then, a nine-valent HPV vaccine (protecting against nine HPV types) was introduced on the market in 2015. Moreover, as more and more EU/EEA Member States consider offering HPV vaccination to boys, this raised questions on the effectiveness and cost-effectiveness of this measure. The new guidance also looks at evidence on HPV vaccine efficacy and effectiveness for people living with HIV given the higher risk to them of HPV infection and HPV-related illness.
The current “Guidance for the introduction of Human papillomavirus (HPV)vaccines in EU countries: focus on nine-valent HPV vaccine, vaccination of boys and of people living with HIV” systematically looks at further updated evidence on these topics and provides more solid conclusions based on the additional research that has been performed in the last six years. The guidance, once finalised, will provide support to decision-making at the national level in relation to HPV vaccination strategies. The primary target audiences are public authorities, national policymakers, entities responsible for the planning of healthcare and social support systems, staff working in national vaccination programmes and professional society organisations with an interest in HPV and/or immunisation programmes.
About the consultation
The deadline for submission of comments by stakeholders and interested parties is 29 April 2019. Comments should be submitted using a specific template and sent to ECDC.HPVguidance@ecdc.europa.eu. Consult the detailed guidelines for the submission of contributions. Only contributions following ECDC guidelines will be considered. For more information on the processing of personal data in the context of this consultation, read the specific privacy statement.
Human papillomavirus (HPV) is one of the most widespread and common sexually transmitted infections worldwide and is often acquired soon after onset of sexual activity. A persistent infection of the genital tract by certain specific types of the HPV virus is the primary cause of anogenital warts, cervical cancer and other anogenital cancers. Potentially, the bivalent and the quadrivalent vaccines could prevent 71% of all cervical cancer cases worldwide. With the nine-valent vaccine, this could go up to 89%. All EU/EEA Member States have introduced HPV vaccination in their national immunisation programmes. These programmes target pre-adolescent girls within the age range of 914 years old through organised school-based immunisation. Recently, several countries have also expanded vaccination to boys of the same age.
Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union. Each year, there are around 33 000 cases of cervical cancer in the EU, and 15 000 deaths. The primary cause of cervical cancer is a persistent infection of the genital tract by some specific types of human papillomavirus (HPV).Read more
Immunisation and vaccines
Vaccines represent one of the most effective and cost-saving public health intervention.Read more